6-19-06

PTO/SB/21 (09-04) 6 3 5

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| TRANSMITTAL FORM | | Application Number | | 10/078,949 | | |
|---|-----------------|--|------------------------------|---|--|---|
| | | Filing Date | | February 22, 2002 | | |
| | | First Named Inventor | | Stanley T. Crooke | | |
| 1 6 5000 R | Art Unit | | 1635 | | | |
| (to be used for all correspondence after | initial filing) | Examiner Name | | Sean McGarry | | |
| Volate of Pages in This Submiss | ion | Attorney Docket Nu | ımber | ISIS0002- | 103 (ISIS-5027) | |
| | ENCLO | SURES (check all that | SURES (check all that apply) | | | |
| Fee Transmittal Form | ☐ Drawing(s | 3) | | After Allowance Communication to TC | | - |
| Fee Attached | Licensing | -related Papers | | Appeal Communication to Board of Appeals and Interferences | | |
| Amendment / Reply | Petition | | . — | | unication to TC Brief, Reply Brief) | |
| ☐ After Final | _ | Convert to a all Application | | Proprietary Inf | ormation | |
| Affidavits/declaration(s) | | Attorney, Revocation f Correspondence | | Status Letter | | |
| Extension of Time Request | Terminal I | Disclaimer | | Other Enclosi | | |
| Express Abandonment Request | | ' | | rms PTO SB/08a and SB/08b (2 pp.); (12) ferences Cited, (0) References Enclosed. | | |
| Supplemental Information Disclosure Statement | ☐ Lan | dscape Table on CD | able on CD | | | |
| Certified Copy of Priority Document(s) | Remarks EXPRESS | MAIL LABEL NO: EV514686517US | | | | |
| Reply to Missing Parts/ Incomplete Application | DATE OF I | DEPOSIT: 16 JUNE 2006 | | | | |
| Reply to Missing Parts under 37 CFR1.52 or 1.53 | ISEV. | 5146865 | 170 | \mathbf{z} | | |
| SIG | NATURE OF A | APPLICANT, ATTOR | RNEY, O | RAGENT | - · | |
| Firm | Cozen O'Conno | | | | | |
| Signature Put | | K Ly | | | | |
| Printed Name Paul K. Legaard | | I, Ph.D. | | | | |
| Date 16 JUNE | | 2006 | Reg. No. | 38,534 | | |
| CERTIFICATE OF TRANSMISSION/MAILING | | | | | | |
| I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below. | | | | | | |
| Signature | | | | | | |
| Typed or printed name | | | Date | | | |

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

n Re Application of: Stanley T. Crooke

Serial No.: 10/078,949

Group Art Unit: 1635

Filing Date: February 20, 2002

Examiner: Sean McGarry

For: Oligoribonucleotides and Robonucleases for Cleaving RNA

EXPRESS MAIL LABEL NO: EV514686517US DATE OF DEPOSIT: 16 JUNE 2006

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56 and in accordance with 37 C.F.R. §§ 1.97 and 1.98, information relating to the above-identified application is hereby disclosed, the Examiner in charge of the above-identified application is requested to consider and make of record the references listed on the PTO Forms SB/08A and SB/08B, formerly known as PTO Form 1449, submitted herewith.

Inclusion of the information submitted herewith is not to be construed as an admission that the information is material as that term is defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. § 1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made.

This Supplemental Information Disclosure Statement is being filed:

| Ш | within three months of the filling date of the patent application. |
|---|--|
| | within three months of the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 of the international application. |
| | before the mailing date of a first Office Action on the merits. |
| | before the mailing date of a first Office Action on the merits after the filing of a Request for Continued Examination under § 1.114. |
| | after the mailing date of a first Office Action on the merits or after the filing of a Request for Continued Examination under § 1.114, but before the mailing |

| | | f a Final Office Action under 37 C.F.R. § 1.116 or a Notice of ance under 37 C.F.R. § 1.311, and accordingly is accompanied by: |
|-------------|-----------------------------|---|
| | | the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below); |
| | or | |
| | | the Fee of \$180.00 set forth in 37 C.F.R. § 1.17(p); or |
| | | No fee is owed by the applicant(s). |
| | Staten Final S C.F.R. | ordance with 37 C.F.R. § 1.129(a), this Information Disclosure nent is being filed in connection with the first or second After Submission, and accordingly is accompanied by the Statement under 37 . § 1.97(e) (see "Statement" below) and the fee of \$180.00 as set forth in F.R. § 1.17(p), is attached. |
| | Notice with, t | he mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a of Allowance under 37 C.F.R. § 1.311, but before, or simultaneously he payment of the Issue Fee, and accordingly is accompanied by the nent under 37 C.F.R. § 1.97(e), and the Fee of \$180.00 set forth in 37 §1.17(p). |
| \boxtimes | • | s of the references listed on the attached PTO Forms SB/08A and B, formerly known as PTO Form 1449, are not enclosed. |
| EXCE | EPT TH | IAT: |
| | | In view of the voluminous nature of references, and the likelihood that these reference are available to the Examiner, copies are not enclosed herewith. |
| | | In accordance with 37 C.F.R. § 1.98(d), copies of the following references listed on the attached PTO Form SB/08A and PTO Form SB/08B, formerly known as PTO Form 1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) 09/479,783 for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application. |
| | | If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request. |
| Staten | nent un | der 37 C.F.R. § 1.97(e) |
| | in the foreign | Information Disclosure Statement was cited in a communication from a patent office in a counterpart foreign patent application not more than nonths prior to the filing of the Information Disclosure Statement. |

Paul K. Legaard, Ph.D. Registration No. 38,534

| State | ment under 37 C.F.R. § 1.704(d) |
|-------------|--|
| | The undersigned attorney hereby states that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and the communication was not received by any individual designated in §1.56(c) more than 30 days prior to the filing of the Information Disclosure Statement. |
| Fees | |
| \boxtimes | No Fee is owed by the applicant(s). |
| | The Supplemental Information Disclosure Statement Fee of \$180.00 under 37 C.F.R. § 1.17(p) is enclosed herewith. |
| | The Petition Fee of \$130.00 under 37 C.F.R. § 1.17(i)(1) is enclosed herewith. |
| Meth | od of Payment of Fees |
| | Attached is a check in the amount of \$ This form is submitted in duplicate. |
| | Charge Deposit Account No. 50-1275 in the amount of \$180.00. This form is submitted in duplicate. |
| | Please charge any deficiency or credit any overpayment to Deposit Account 50-1275. |
| | No fee or Statement is required under 37 C.F.R. § 1.97(b). |
| | Respectfully submitted, |
| | |

Dated: 16 JUNE LOOP

COZEN O'CONNOR, P.C. 1900 Market Street, 5th Floor Philadelphia, PA 19103-3508 (215) 665-2000 – Telephone (215) 665-2013 - Facsimile

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE ct of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO Complete if Known Application Number 10/078,949 INFORMATION DISCLOSURE Filing Date February 20, 2002 STATEMENT BY APPLICANT First Named Inventor Stanley T. Crooke Art Unit 1635 (Use as many sheets as necessary) Examiner Name Sean McGarry Sheet of 2 ISIS0002-103 (ISIS-5027) Attorney Docket Number

| | U.S. PATENT DOCUMENTS | | | | | |
|---------------|-----------------------|--|------------------------|----------------------------------|---------------------------------------|--|
| Examiner Cite | | Document Number | Publication/Issue Date | Name of Patentee or Applicant of | Pages, Columns, Lines, Where Relevant | |
| Initials * | No.1 | Number - Kind Code ² (if known) | MM-DD-YYYY | Cited Document | Passages or Relevant Figures Appear | |
| | AA | US-5,898,031 | 04-27-1999 | Crooke et al. | | |
| /SN | / AB | US-6,849,726 | 02-01-2005 | Usman et al. | | |
| | | US- | | | | |
| | | US- | | | | |
| | | US- | | | | |
| | | US- | | | | |
| | | US- | | | | |
| | | US- | | | | |
| | | US- | | | | |
| | | US- | - | | | |
| | | US- | | | | |
| | | US- | | | - | |
| | | US- | | | | |
| | | US- | | | | |
| | | US- | | | | |
| | | US- | | | | |
| | | US- | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|---|-------------------------|---|--------------------------------|--------------------------------|--|----|
| Examiner Cite | Foreign Patent Document | Publication | Name of Patentee or | Pages, Columns, Lines, | | |
| Initials* | No. ¹ | Country Code ³ - Number ⁴ - Kind Code ⁵ (if known) | Date/Filing Date MM-DD-YYYY | Applicant of Cited Document | Where Relevant Passages or Relevant Figures Appear | T⁵ |
| , ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, | AC | WO 97/46570 | 12-11-1997 | ISIS Pharm | | |
| | AD | WO 00/63364 | 10-26-2000 | Am Home Products | | |
| $\overline{\mathcal{M}}$ | AE | DE 101 00 588 | 07-18-2002 | Ribopharma | | |
| (O) (1) | AF | EP 339842 | 11-02-1989 | Ajinomoto Co. | | |
| /SM/ | AG | WO 93/07883 | 04-29-1993 | ISIS Pharm. | | |
| | | | | | | |
| | | | | | | |
| | 1 | | | | | |

| Examiner Signature | Date Considered | |
|-----------------------|--------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwood Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for the BACO TO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

| Complete if Known | | | |
|------------------------|--------------------------|--|--|
| Application Number | 10/078,949 | | |
| Filing Date | February 20, 2002 | | |
| First Named Inventor | Stanley T. Crooke | | |
| Art Unit | 1635 | | |
| Examiner Name | Sean McGarry | | |
| Attorney Docket Number | ISIS0002-103 (ISIS-5027) | | |

| | | NON PATENT LITERATURE DOCUMENTS | |
|--|------|---|----|
| Examiner Initials * Cite No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | | | Τ² |
| /SM/ | AF | Hamilton et al., "A species of small antisense RNA in posttranscriptional gene silencing in plants," Science (1999) 286(5441):950-952. | |
| /SM/ | AG | Hunter, "Genetics: a touch of elegance with RNAi," Current Biology, Current Science (1999) 9(12):R440-R442. | |
| /SM/ | AH | Kumar et al., "Antisense RNA: function and fate of duplex RNA in cells of higher eukaryotes," Microbiology and Molecular Biology Reviews (1998) 62(4):1415-1434. | |
| /SM | / AI | Opalinska et al., "Nucleic-acid therapeutics: basic principles and recent applications," Nature Reviews (2002) 1:503-514. | |
| /SM | / AJ | Milligan et al., "Current concepts in antisense drug design," J of Medicinal Chemistry (1993) 36(1):1923-1927. | |
| : | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| Examiner | /Sean Mcgarry/ | Date | 10/09/2007 |
|-----------|----------------|------------|------------|
| Signature | | Considered | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gather any depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.